6534.TW CH Biotech R&D Co., Ltd.
- Market cap
- TWD 8.62B
- P/E
- 14.5x
- P/B
- 3.27x
- ROE
- -
- Dividend yield
- 4.89%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6534.TW undervalued?
Graham number6534.TW trades 45.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CH Biotech R&D Co., Ltd. fundamental analysis
No fundamental analysis for CH Biotech R&D Co., Ltd. yet.
CH Biotech R&D Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers, biostimulants, and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
Full company profileCH Biotech R&D Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CH Biotech R&D Co., Ltd. annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 841M | 702M | 1.02B | 1.43B | 1.51B | 1.64B | 1.82B | 2.07B |
| Gross Profit | 697M | 590M | 848M | 1.13B | 1.26B | 1.36B | 1.36B | 1.74B |
| Operating Income | 258M | 150M | 373M | 582M | 566M | 542M | 623M | 821M |
| EBITDA | 352M | 248M | 470M | 722M | 762M | 798M | 837M | 969M |
| Net Income | 190M | 100M | 291M | 465M | 463M | 476M | 464M | 703M |
| EPS | 1.94 | 1.03 | 2.97 | 4.72 | 4.73 | 4.61 | 4.51 | 6.37 |
| Balance Sheet | ||||||||
| Total Assets | - | 2.88B | 3.03B | 3.20B | 3.65B | 3.63B | 3.57B | - |
| Total Liabilities | - | 1.40B | 1.31B | 1.11B | 1.13B | 982M | 888M | - |
| Shareholders' Equity | - | 1.48B | 1.72B | 2.09B | 2.52B | 2.65B | 2.69B | - |
| Cash & Short-term Investments | 715M | 330M | 327M | 533M | 943M | 482M | 397M | - |
| Total Debt | - | 1.30B | 1.12B | 895M | 845M | 747M | 664M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | - | 233M | 264M | 699M | 659M | 538M | 589M | 1.56B |
| Capital Expenditure | 0.00 | 109M | 71.9M | 118M | 116M | 590M | 123M | 184M |
| Free Cash Flow | - | 124M | 192M | 581M | 543M | -51.5M | 466M | 1.37B |
| Ratios | ||||||||
| ROE | - | 6.8% | 16.9% | 22.3% | 18.4% | 18.0% | 17.3% | - |
| ROA | - | 3.5% | 9.6% | 14.6% | 12.7% | 13.1% | 13.0% | - |
| Net Profit Margin | 22.7% | 14.3% | 28.6% | 32.5% | 30.6% | 29.1% | 25.5% | 34.0% |
| Debt to Equity | - | 0.88x | 0.65x | 0.43x | 0.34x | 0.28x | 0.25x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CH Biotech R&D Co., Ltd. dividends
- Dividend yield
- 4.89%
- Forward dividend
- 5.31 TWD
- Payout ratio
- 90.9%
- Ex-dividend date
- Sep 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 421M | 4.10 | 90.9% |
| 2024 | TWD 369M | 3.57 | 77.5% |
| 2023 | TWD 474M | 4.84 | 102.3% |
| 2022 | TWD 127M | 1.28 | 27.2% |
| 2021 | TWD 42.2M | 0.43 | 14.5% |
| 2020 | 88.4M | 0.91 | 88.3% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1150:1000 on Jul 26, 2022.
Who owns CH Biotech R&D Co., Ltd.
Ownership data of CH Biotech R&D Co., Ltd. is not available yet.
CH Biotech R&D Co., Ltd. company profile
- Company name
- CH Biotech R&D Co., Ltd.
- Ticker
- 6534.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Fiscal year end
- December
- Address
- Chung Hsing Park, Central Taiwan Science Park, Nantou City, Taiwan, 54041
- Phone
- 886 4 9700 9198
- Website
- chbio.com
About CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers, biostimulants, and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
CH Biotech R&D Co., Ltd. management
5- Wen Ren ChenManager
- Ms. Hsiu-Feng LinAssistant Vice President of Finance Department
- Xinjun LuoAccounting Supervisor
- Mr. Mu-Sheng LinChief of Board Office
- Mr. Kuei-Chun LiHead of R&D Department